熱門資訊> 正文
ImmuCell任命Olivier te Boekhorst为首席执行官
2025-09-30 04:13
- 伊芙美爾醫療(ICCC) 0
- 塞拉尼斯(CE) 0
- 纳比特(NA) 0
- ImmuCell (NASDAQ:ICCC) announced that it has selected Olivier te Boekhorst as its next President and CEO, anticipating a start date of November 1, 2025.
- The company said te Boekhorst is currently an operating partner at ARCHIMED, a global investment firm focused on human and animal healthcare industries, and serves as chair of the Board of SeqCenter, where he previously served as CEO. From 2004 to 2022, he held several leadership roles at Maine-based global diagnostics leader IDEXX Laboratories.
- ICCC -3.04% after hours to $5.914.
- Source: Press Release
More on ImmuCell
- ImmuCell outlines cautious H2 outlook as capacity expansion supports First Defense suite
- Financial information for ImmuCell
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
